Protocol No.: 11VR1.1; A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults with Growth Hormone Deficiency